Evidence map›Paper›PMID 42325270›Full record

ArticleiScience2026

Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity.

Sven Kratochvil, Maximilian Kullmann, Henning Gruell, Sophie Sayettat, Chia-Hung Tsai, Natasa Vukovic, Christine Janaitis, Claudia Lindemann, Sandra Praßl, Ricarda Stumpf and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sven KratochvilBioNTech SE, Mainz, Germany.
Maximilian KullmannBioNTech SE, Mainz, Germany.
Henning GruellInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Sophie SayettatInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Chia-Hung TsaiBioNTech US Inc., Cambridge, MA, USA.
Natasa VukovicBioNTech SE, Mainz, Germany.
Christine JanaitisBioNTech SE, Mainz, Germany.
Claudia LindemannBioNTech UK Ltd, London, UK.
Sandra PraßlBioNTech SE, Mainz, Germany.
Ricarda StumpfInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jacqueline KnüferInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Felix TolksdorfBioNTech SE, Mainz, Germany.
Uğur ŞahinBioNTech SE, Mainz, Germany.
Johannes NelkeBioNTech SE, Mainz, Germany.
Alexandra MalzBioNTech SE, Mainz, Germany.
Philipp SchommersDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Sinethemba BhebheSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Nonhlanhla MkhizeSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Penny MooreSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Florian KleinInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Valentin Le DouceBioNTech SE, Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Broadly neutralizing antibody (bNAb) 1-18 is a promising tool for future clinical strategies against HIV-1 infection. To enhance 1-18's clinical potential, we introduced half-life-extending LS mutations and evaluated the resulting investigational bNAb candidate, BNT351. LS mutations increased the affinity of BNT351 to human neonatal Fc receptor by 20-fold, resulting in a long half-life of 10-14 days in Tg32 mice and 18 days in non-human primates, with a predicted human half-life of ∼50 days. BNT351 retained 1-18's exceptional neutralization potency and breadth against a 119 multiclade panel, and neutralized a pseudovirus panel of circulating HIV-1 clade C strains with high potency. BNT351 fully suppressed viremia in HIV-1-infected humanized CD34

Indexed as

antibody therapybiotechnologybNAbHIV-1Immunologypharmacokineticsvirology

Identifiers

PMID42325270
PMCPMC13276592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.